All News

The Crohn’s disease Exclusion Diet may help to increase the food options available for many children with the condition.

Asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze) is approved for use as a component of a chemotherapy regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma

The investigators said that attention-grabbing anti-vaccine arguments, regardless of scientific basis, as well as an overall distrust of the pharmaceutical industry, science, and health providers, seems to be primarily responsible.

Research presented at the Alzheimer’s Association International Conference (AAIC) 2021 found associations between COVID-19 and persistent cognitive deficits, including the pathology and symptoms of Alzheimer disease.

BCC is the most common form of skin cancer and is typically treated with surgical excision. However, excision can be a costly and burdensome treatment, especially for patients with multiple BCC lesions, according to the study.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The study sample included female patients between 36 and 61 years of age, and in all cases, the baseline rheumatic disease was either mild or stable under medical treatment.

The new format being rolled out at Rite Aid stores is designed to center pharmacists and make them easily accessible to patients.

Although ADHD is generally treated through medication and/or behavioral treatments, in more than 25% of children, these treatments alone are insufficient.

C difficile colonization rates among children were greatest at 6 to 12 months of age but decreased among children older than 5 years of age.

Avalglucosidase alfa-ngpt is indicated for patients aged 1 year and older with late-onset Pompe disease.

In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

A stepwise approach to treatment for multisystem inflammatory syndrome, beginning with initiation of immunomodulatory drugs, was successful in all patients included in the study.

Patients with COVID-19 who were vaccinated against the flu were found to be significantly less likely to visit the emergency department and be admitted to the intensive care unit.

Telemedicine visits with a clinical pharmacist offer many advantages, such as social distancing, flexible scheduling, and the ability to use nonverbal cues to convey understanding.

Findings reflect fewer visits to health facilities, social distancing, and other safety measures implemented during the pandemic.

Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA), which is an antigen presenting cell (APC) inducer.

Study suggests attention-deficit hyperactivity disorder medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.

Antidepressants may lower the risk of death and serious complications from diabetes for patients with both diabetes and depression, according to a study published in the Journal of Clinical Endocrinology & Metabolism.

Forced exhalation volume in one second and forced vital capacity can determine the stage severity for chronic obstructive pulmonary disease.

A generic TDF/FTC costs as low as $30 per month, compared with about $1800 per month for branded TAF/FTC

Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.

Study examines whether dapagliflozin is cost-effective when added to standard of care for patients who have heart failure with reduced ejection fraction.

In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.

According to the investigators, the findings demonstrate that a 5-day regimen of stereotactic body radiotherapy, a form of external beam radiation therapy that uses a higher dose of radiation, had a 4-year cure rate of 82%.

Top-line data from the NORSE TWO trial demonstrated that the treatment met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.